摘要
Abstract
Objective To systemic evaluate the clinical efficacy and safety of Yangzhengxiaoji capsule combined with interventional chemotherapy or radiotherapy in the treatment of primary liver cancer .Methods Computer retrieval PubMed , EM and base, CNKI, Wanfang Data, Chinese doctoral dissertations full text database , China outstanding master's Degree Dis-sertation Full-text data, comprehensive collected all randomized controlled trials of Yangzhengxiaoji capsule in the treatment of primary hepatocellular carcinoma (HCC).Meta-analysis was performed using RevMan 5.3 software.Results A total of 8 lit-eratures were included , and a total of 1 868 patients were included .Meta-analysis results showed:compared the experimental group and the control group , recent effect of treating solid tumor (OR=1.36, 95%CI 1.12-1.65, P =0.002), quality of life (OR=1.96, 95%CI 1.52-2.54, P <0.01) and body mass increased rate (OR=1.97, 95%CI 1.45-2.66, P <0.01) were significant different;the white blood cells decreased rate (OR=0.35, 95%CI 0.25-0.50, P <0.01), platelet decreased rate (OR=0.39, 95%CI 0.28-0.54, P <0.01) and nausea vomiting occurred rate (OR=0.30, 95%CI 0.21-0.41, P <0.01)’s differences were different statistical significance .Conclusion Yangzhengxiaoji capsule combined with interventional chemotherapy or radiotherapy in the treatment of primary hepatocellular carcinoma can decrease tumor size , im-prove life quality , raise the quality of donor and reduce the adverse effects of radiotherapy and chemotherapy .关键词
养正消积胶囊/原发性肝癌/Meta分析/系统评价/随机对照试验Key words
Yangzhengxiaoji capsule/Primary hepatocellular carcinoma/Meta-analysis/System evaluation/Ran-domized controlled trials
